DURHAM, N.C., Aug. 5 /PRNewswire/ -- Chesson Labs today announced receiving 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for NUVADERM(TM), the Company’s liquid bandage product. The 510(k) clearance allows Chesson Labs to market and sell the product for use by healthcare professionals and directly to consumers.
NUVADERM’s clearance is a significant milestone for Chesson Labs because it is their first medical device submission to the FDA and first 510(k) clearance. The Company anticipates submission of additional filings to the FDA as it continues to expand its product portfolio.
ABOUT CHESSON LABS
Chesson Labs is headquartered in the University Tower in Durham, NC. For more information, visit www.chessonlabs.com or call 919-419-4900.
SOURCE Chesson Labs
CONTACT: CONTACT: Scott E. Neuville, President & CEO of Chesson Labs,
+1-919-419-4900 (office)
Web site: http://www.chessonlabs.com/
